Myoepithelial Carcinoma: A Rare Neoplasm of the Breast

Kuo-Chun Liao\textsuperscript{a}  Wen-Ying Lee\textsuperscript{b}  Ming-Jenn Chen\textsuperscript{a}

\textsuperscript{a}Department of Surgery,  
\textsuperscript{b}Department of Pathology, Chi Mei Medical Center, Yong Kang City Tainan, Taiwan, R.O.C.

Key Words  
Malignant myoepithelioma · Breast neoplasm · p63 · Surgical oncology

Summary

Background: Malignant myoepitheliomas of the breast are extremely rare. There has been a limited number of published reports of myoepithelial carcinomas originating from the breast. Case Report: We describe a malignant myoepithelioma of the breast in a 56-year-old woman. Histological examination showed polygonal epithelioid cells and spindle cells with moderate to marked nuclear atypia. Immunohistochemistry showed reactivity in the spindle cells for smooth muscle actin, cytokeratin (AE1/AE3), and p63, indicating a myoepithelial cell lineage of tumor cells. The patient underwent radical surgical excision of the lesion and axillary lymph node dissection. She demonstrated no evidence of recurrence over an 11-month follow-up. Conclusions: We suggest myoepithelial carcinomas of the breast be managed with appropriate surgical clearance. A multidisciplinary approach is usually required.

Introduction

Myoepithelial cells of the breast are present as an intervening layer in the normal mammary glandular structures, located between the epithelial cells and the basement membrane of the secretory elements of the mammary duct system. They have important roles in mammary gland development and physiology. Furthermore, myoepithelial cells maintain the basement membrane surrounding the mammary ducts, and provide a physical barrier between epithelial cells and the stroma. Myoepithelial cells have dual structural characteristics of epithelial and smooth muscle cells [1]. The most common location of myoepitheliomas is the salivary gland [2–4]. Extrasalivary locations include soft tissue, skin, breast, and lung. Myoepithelial carcinoma of the breast is composed of malignant myoepithelial cells which are usually spindle-shaped but may occasionally be polygonal. Mammary tumors with predominantly myoepithelial elements are extremely uncommon.
Case Report

A 56-year-old, postmenopausal woman presented to a medical center with a palpable mass in the left breast 1 month before admission to our hospital. Physical examination disclosed a firm, movable mass of 3.5 × 2.5 cm in size in the lower inner quadrant of the left breast. No masses or lymphadenopathy were palpable in the axilla. The remainder of the examination was unremarkable. The patient had an 18-year history of rheumatoid arthritis and type 2 diabetes mellitus. Menarche had occurred at the age of 13 years, and she had been pregnant 4 times (first pregnancy at the age of 28 years) and given birth 2 times. She had never used oral contraceptives or received exogenous hormone replacement therapy. The patient had never smoked cigarettes, and would occasionally drink 1–2 alcoholic beverages. There was no family history of breast cancer.

Mammography revealed regional architectural distortion (fig. 1 A). Ultrasound showed a 27 × 18 × 30 mm mass with an irregular, ill-defined and hypoechoic appearance (fig. 1 B). The histological examination of a simultaneous core biopsy revealed the presence of atypical myoepithelial cells. After options were discussed, the patient elected to undergo a wide excision. Pathological examination revealed that the tumor extended with an infiltrative border into the nearby structures. The neoplasm was composed of polygonal, epithelioid cells and spindle cells with moderate to marked nuclear atypia (fig. 2 A). Mitotic figures were readily identifiable. Immunohistochemistry showed strong immunoreactivity for smooth muscle actin, cytokeratin (AE1/AE3), and p63, indicating a myoepithelial cell lineage of tumor cells (fig. 2 B). Ki-67 immunostaining exhibited a proliferation rate of around 30%. The lesion was diagnosed as a malignant myoepithelioma. As the surgical margins were positive, a modified radical mastectomy with axillary lymph node clearance was performed, which left no residual foci of malignancy. No metastasis was detected in the axillary lymph nodes. In 11 months of follow-up, there has been no evidence of recurrence.

Discussion

Tavassoli [5] proposed that there are 3 types of myoepithelial lesions in the breast: myoepitheliosis, adenomyoepithelioma, and malignant myoepithelioma. Myoepitheliosis and adenomyoepitheliomas consist of a significant population of myoepithelial cells admixed with epithelial cells. Adenomyoepitheliomas are further classified into spindle cell, tubular, and lobulated variants based on the growth patterns. Malignant myoepithelioma is composed purely of myoepithelial cells. It is an extremely rare tumor.

Myoepithelial carcinomas are difficult to diagnose. Unlike adenomyoepitheliomas, which exhibit distinctive combined patterns of luminal epithelial and myoepithelial differentiation [6, 7], they are composed purely of spindle cells, and consequently virtually impossible to differentiate from spindle cell carcinomas and sarcomas on morphological examination [8–10]. It is essential to be able to recognize myoepithelial carcinomas in order to learn more about their natural history and response to treatment. Myoepithelial carcinomas are characterized by an infiltrating proliferation of plump, atypical spindle cells with readily identifiable mitotic figures [8–10]. These tumors are composed purely of spindled cells without any epithelial cell component. Although most malignant myoepitheliomas are of the spindle cell type, glandular type epithelial structures with lumen and microvilli have been demonstrated ultrastructurally. It is important to distinguish myoepithelial carcinoma from other forms of breast lesions composed of spindle cells. These mainly include monophasic sarcomatoid carcinoma, fibromatosis, and pure spindle cell sarcoma [11]. Overlap in their histological appearances may lead to misinterpretation or underdiagnosis.

Monophasic sarcomatoid carcinomas contain little or no discernible epithelial component. Some monophasic sarcomatoid carcinomas may co-express actin immunoreactions, making separation from myoepithelial carcinoma difficult. The diagnosis is usually established using antibodies to keratin of variable molecular weight. Sarcomatoid carcinomas behave in a manner similar to that of high-grade carcinomas [12, 13]. Fibromatosis is well recognized in the breast. The diagnosis is mainly based on histological features. It is composed of proliferation of myofibroblasts and fibroblasts which comprise fascicles of spindle cells with usually minimal pleomorphism and few or no mitoses [14, 15]. Immunohistochemically, fibromatosis often expresses actin, and occasionally desmin and S100. Cytokeratins are not expressed [16]. It is important to exclude the deceptively bland monophasic sarcomatoid carcinoma before contemplating a diagnosis of fibromatosis. Pure spindle cell sarcomas should only be diagnosed after being distinguished from other resembling lesions, including spindle cell myoepithelioma [8] and monophasic sarcomatoid carci-
oma [13, 14]. Immunohistochemical and ultrastructural examinations are usually helpful in making a differential diagnosis, showing a lack of epithelial components in most pure spindle cell sarcomas of the breast. The presence of S100 protein and focal positivity for cytokeratin favors a myoepithelioma.

The patient’s clinical picture is consistent with a myoepithelial carcinoma of breast according to histological characteristics and expression of immunohistochemical positivity for cytokeratin and myoepithelial markers. The patient had a complete excision of the lesion without receiving adjuvant radiotherapy, chemotherapy, or hormone therapy. So far, the regular follow-up evaluations adopt an uneventful course.

Over the past decade, there has been significant progress in the discovery and application of antibody markers that can be used in the immunohistochemical identification of myoepithelial cells. Myoepithelial cells can be difficult to detect on routine section. Increasing attention has been given to the aiding role of immunohistochemical stains [17–20]. For optimal clinical utility, an ideal marker of myoepithelium would manifest absolute sensitivity and specificity for myoepithelial cells. In particular, such a marker would not cross-react with other cells in the breast, such as stromal myofibroblasts, vascular smooth muscle cells, or luminal epithelial/carcinoma cells. Currently widely used myoepithelial markers include S100 protein, the basement membrane proteins, type IV collagen and laminin, high molecular weight cytokeratins, and smooth muscle actins, all having incomplete sensitivities and specificities that make them imperfect candidate myoepithelial markers. P63, a homologue of p53, is a sensitive and relatively specific marker for myoepithelial cells [21–24]. It is a nuclear stain with high sensitivity and minimal cross-reactivity. It is not expressed in myofibroblasts or blood vessels, therefore circumventing the diagnostic pitfalls associated with smooth muscle-related myoepithelial markers. Overall, p63 has high sensitivity and specificity for myoepithelial cells and is a very useful marker.

In conclusion, myoepithelial carcinomas are extremely rare lesions of the breast. Myoepithelial carcinomas are difficult to diagnose. The development of immunohistochemistry aids in the histological examination of breast in which identification of myoepithelial carcinoma is not feasible from the morphological features alone. Myoepithelial carcinomas pursue an aggressive clinical course with locally invasive and metastatic potential [25, 26]. Radical excision with elective adjuvant radiotherapy is the therapeutic strategy of choice in order to minimize local recurrence. Multiple aspects including age, comorbidity, and the patient’s autonomy should be taken into consideration while drawing a treatment plan. To date, there is limited published data on the biological behavior and long-term clinical outcome of mammary myoepithelial carcinomas. We therefore recommend a multidisciplinary approach based on an experienced team to formulate a treatment modality.

Conflict of Interest

The authors declare no conflict of interest.

References

9. Tavassoli FA: Myoepithelial lesions of the breast. Myoepithelial carcinomas are difficult to diagnose. The development of immunohistochemistry aids in the histological examination of breast in which identification of myoepithelial carcinoma is not feasible from the morphological features alone. Myoepithelial carcinomas pursue an aggressive clinical course with locally invasive and metastatic potential [25, 26]. Radical excision with elective adjuvant radiotherapy is the therapeutic strategy of choice in order to minimize local recurrence. Multiple aspects including age, morbidity, and the patient’s autonomy should be taken into consideration while drawing a treatment plan. To date, there is limited published data on the biological behavior and long-term clinical outcome of mammary myoepithelial carcinomas. We therefore recommend a multidisciplinary approach based on an experienced team to formulate a treatment modality.

In conclusion, myoepithelial carcinomas are extremely rare lesions of the breast. Myoepithelial carcinomas are difficult to diagnose. The development of immunohistochemistry aids in the histological examination of breast in which identification of myoepithelial carcinoma is not feasible from the morphological features alone. Myoepithelial carcinomas pursue an aggressive clinical course with locally invasive and metastatic potential [25, 26]. Radical excision with elective adjuvant radiotherapy is the therapeutic strategy of choice in order to minimize local recurrence. Multiple aspects including age, comorbidity, and the patient’s autonomy should be taken into consideration while drawing a treatment plan. To date, there is limited published data on the biological behavior and long-term clinical outcome of mammary myoepithelial carcinomas. We therefore recommend a multidisciplinary approach based on an experienced team to formulate a treatment modality.

Conflict of Interest

The authors declare no conflict of interest.

References


